HBV感染者病毒基因型分布特点及其与干扰素疗效的关系

doi:10.3969/j.issn.1672-5069.2014.03.021

Abstract

Jiang Jie, Huang Xinyan, Wang Lihong. Hepatitis B virus genotypes and its correlation to interferon-α therapy in patients with hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 299-301.

[1] Liaw YF,Kao JH,Piratvisuth T,et al. Asian-pacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatol Int,2012,27（6）:531-561.
[2] 夏淑林,张振华,叶珺,等. 恩替卡韦治疗慢性乙型肝炎患者疗效观察. 实用肝脏病杂志,2011,14（3）:183-184.
[3] Tanaka Y,Hasegaw aI,Kato T,et al. A case control study for differences among hepatitis B virus infect ions of genotypes A ( subtypes Aa and Ae） and D. Hepatology,2004,40（3）：747-755.
[4] Yu H,Yuan Q,Ge SX,et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype“I”. PLoS ONE,2010,5（2）:1-9.
[5] Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol,2009,15（46）:5761-5769.
[6] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）:81-89.
[7] 慢性乙型肝炎抗病毒治疗专家委员会. 慢性乙型肝炎抗病毒治疗专家共识. 中华实验和临床感染病杂志（电子版）,2010,4（1）:82-91.
[8] 张志珊,苏智军,林毅胜,等. 泉州地区慢性乙型肝炎患者HBV 基因型、基因亚型及血清型分布调查. 中国人兽共患病学报,2010,26（11）:1037-1040.
[9] Thakur V,Guptan RC,Kazim SN,et al. Profile,spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol,2002,17（2）:165-170.
[10] Norder H,Courouce AM,Magnius LO. Complete genomes, phylogenetic relatedness,and structural proteins of six strains of the hepatitis B virus,four of which represent two new genotypes. Virology,1994,198（9）:489-503.
[11] Ding X,Mizokami M,Yao G,et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai,China. Intervirology,2001,44（5）:43-47.
[12] 孙文锦,肖作汉,赵丽芹,等. 乙型肝炎病毒基因分型与疾病病情的关系. 实用肝脏病杂志,2013,16（1）:66-67.
[13] 邰立惠. 替比夫定联合胸腺肽-α1治疗慢性乙型肝炎临床观察. 实用肝脏病杂志,2013,16（6）:541-542.
[14] 李旭红,赖江琼,张小曼,等. 干扰素联合胸腺肽α1再治疗干扰素治疗失败的HBeAg阳性慢性乙型肝炎. 实用肝脏病杂志,2013,16（6）:542-543.
[15] 任红. 追求持久免疫控制:写在聚乙二醇干扰素α上市10周年.中华肝脏病杂志,2013,21（7）:481-483.

Hepatitis B virus genotypes and its correlation to interferon-α therapy in patients with hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.